Merck & Co.
AWARDS
NEWS
It was a busy week for clinical trial updates. Here’s a look.
Merck, known as MSD outside of the U.S. and Canada, announced on Wednesday that it has seen positive results regarding the safety, tolerability and immunogenicity of V114 in two Phase III studies.
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
The new research hub will be called the London Discovery Research Centre and is expected to open by 2025.
Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).
JOBS
IN THE PRESS